Aranesp® | Darbepoetin | Amgen
17 Sep 2020 | Lotus Pharma, Chong Kun Dang | Lotus Pharma announces it has signed a commercialisation agreement with Chong Kun Dang for Nesbell® (biosimilar darbepoetin-alpha). Under the agreement, Chong Kun Dang will supply Lotus with Nesbell® for sale in Taiwan, Vietnam and Thailand pending the success of clinical trials in those countries.
23 Sep 2019 | JP | Dong-A ST, Sanwa Kagaku Kenkyusho | Dong-A ST announces sales approval for biosimilar darbepoetin from Japan's Ministry of Health, Labour and Welfare.
25 July 2019 | All | Kissei/JCR | JCR announces results of Ph III trials of biosimilar darbepoetin candidate JR131 in patients with renal anemia. 159 patients enrolled in the 52 week study, with JCR reporting no adverse drug reactions, and that patient hemoglobin levels remained within the required 10.0 to 12.0 g/dL range throughout the study.
24 Dec 2018 | KR | Chong Kun Dang | Chong Kun Dang announces approval for biosimilar darbepoetin from the Ministry of Food and Drug Safety of South Korea. This is the first biosimilar darbopoetin to be approved in a highly regulated country.